Luis Solorio1, Hanping Wu2, Christopher Hernandez3, Mihika Gangolli4, Agata A Exner2,3. 1. Department of Chemical Engineering, University of Michigan, 2300 Hayward St, Ann Arbor, MI 48109, USA. 2. Case Center for Imaging Research, Department of Radiology, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106-5056, USA. 3. Department of Biomedical Engineering, Case Western Reserve University, OH, USA. 4. Department of Biomedical Engineering, Washington University, MO, USA.
Abstract
BACKGROUND: Hepatocellular carcinomas are frequently nonresponsive to systemically delivered drugs. Local delivery provides an alternative to systemic administration, maximizing the dose delivered to the tumor, achieving sustained elevated concentrations of the drug, while minimizing systemic exposure. RESULTS: Ultrasound-guided deposition of doxorubicin (Dox)-eluting in situ forming implants (ISFI) in an orthotopic tumor model significantly lowers systemic drug levels. As much as 60 µg Dox/g tumors were observed 21 days after ISFI injection. Tumors treated with Dox implants also showed a considerable reduction in progression at 21 days. CONCLUSION: Dox-eluting ISFIs provide a promising platform for the treatment of hepatocellular carcinomas by which drug can be delivered directly into the lesion, bypassing distribution and elimination by the circulatory system.
BACKGROUND:Hepatocellular carcinomas are frequently nonresponsive to systemically delivered drugs. Local delivery provides an alternative to systemic administration, maximizing the dose delivered to the tumor, achieving sustained elevated concentrations of the drug, while minimizing systemic exposure. RESULTS: Ultrasound-guided deposition of doxorubicin (Dox)-eluting in situ forming implants (ISFI) in an orthotopic tumor model significantly lowers systemic drug levels. As much as 60 µg Dox/g tumors were observed 21 days after ISFI injection. Tumors treated with Dox implants also showed a considerable reduction in progression at 21 days. CONCLUSION:Dox-eluting ISFIs provide a promising platform for the treatment of hepatocellular carcinomas by which drug can be delivered directly into the lesion, bypassing distribution and elimination by the circulatory system.
Entities:
Keywords:
drug delivery; hepatocellular carcinoma; in situ forming implant; phase inversion; ultrasound
Authors: Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz Journal: JAMA Date: 2010-11-17 Impact factor: 56.272
Authors: Selva Jeganathan; Emily Budziszewski; Peter Bielecki; Michael C Kolios; Agata A Exner Journal: J Control Release Date: 2020-05-07 Impact factor: 9.776